Novel Therapies May Lead to More Treatment Options in Sarcoma Subtypes

Commentary
Video

CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.

A number of developments are taking place within sarcoma subtypes that may have the potential to impact the standard of care in select patient subgroups, bolstering the armamentarium and potentially resolving unmet needs, according to Sandra P. D’Angelo, MD.

This includes CAR T-cell therapies such as a famitresgene autoleucel (afami-cel), which was investigated in a phase 2 trial (NCT04044768) in a population of patients with advanced synovial sarcoma or myxoid round cell liposarcoma.1 D’Angelo indicated that the product has the potential to become a standard of care in the synovial sarcoma population.

During a conversation with CacnerNetwork®, D’Angelo, a sarcoma oncologist and cellular therapist at Memorial Sloan Kettering Cancer Center, discussed how envafolimab may hold promise in undifferentiated pleomorphic sarcoma (UPS) and expanded on the potential of immune checkpoint inhibitors in dedifferentiated liposarcoma.

Transcript:

A phase 2 trial [utilizing] afami-cel trial has been conducted and completed. Afami-cel targets MAGE-A4, and was found to be quite promising, specifically [in] synovial sarcoma. A BLA is in progress at the moment. We’re optimistic that perhaps it’ll become a new standard of care for patients with synovial sarcoma.

We don’t have many immunotherapy approvals other than atezolizumab [Tecentriq] for alveolar soft-tissue sarcoma, but there’s also an ongoing trial called the phase 2 ENVASARC [NCT04480502] that utilizes checkpoint blockade envafolimab in UPS.2 That trial has the prospect of allowing envafolimab to ultimately be FDA-approved.

There’s a phase 3 trial [NCT04967521] ongoing with abemaciclib [Verzenio], which is a CDK4 inhibitor. Much work has been done with CDK4 blockade and dedifferentiated liposarcoma.3 Much of that work has been led by my colleague at MSKCC [Memorial Sloan Kettering Cancer Center] Mark A. Dickson, MD. This is a pivotal trial, randomizing abemaciclib to placebo to ultimately, hopefully, demonstrate improvement over placebo to lead to advancements in dedifferentiated liposarcoma. There are also a number of other studies [assessing other agents]; for example, MDM2 inhibition has been studied extensively in liposarcoma. There’s now a frontline trial comparing an MDM2 inhibitor to doxorubicin in dedifferentiated liposarcoma.

Those are the trials that are furthest along for development at the moment, and the ones that we think are perhaps closest to impacting the standard of care in the short term.

References

  1. D’Angelo SP, Van Tine BA, Blay JY, et al. SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma. J Clin Oncol. 2021;39(suppl 15):11504. doi:10.1200/JCO.2021.39.15_suppl.11504
  2. TRACON Pharmaceuticals announces results of independent data monitoring committee review of 12 week safety data from ENVASARC phase 2 pivotal trial - trial to proceed as planned. News Release. TRACON. October 6, 2022. Accessed July 20, 2023. https://yhoo.it/3RJSgzW
  3. Dickson MA, Ballman KV, Weiss MC, et al. SARC041: a phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. J Clin Oncol. 2023;41(suppl 16):TPS11587. doi:10.1200/JCO.2023.41.16_suppl.TPS11587

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content